Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation
Authors Yu J, Li W, Yu D
Received 27 February 2018
Accepted for publication 10 April 2018
Published 11 June 2018 Volume 2018:12 Pages 1697—1706
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Georgios D. Panos
Jianjun Yu,1,* Wei Li,2,* Dongmei Yu3
1Department of Emergency, Shandong Jining No 1 People’s Hospital, Jining 272011, Shandong, People’s Republic of China; 2Department of Outpatient, Shandong Jining No 1 People’s Hospital, Jining 272011, Shandong, People’s Republic of China; 3Department of Public Health, Shandong Jining No 1 People’s Hospital, Jining 272011, Shandong, People’s Republic of China
*These authors contributed equally to this work
Purpose: Myocardial infarction is a major cause of mortality and heart failure worldwide. One of the most effective methods of this injury is direct delivery of cardioprotective drugs to ischemia–reperfusion (IR) myocardium. The aim of the present study was to fabricate an adenosine (Ade) prodrug-based, atrial natriuretic peptide (ANP)-modified nanosystem for the treatment of myocardial infarction.
Materials and methods: Oleate adenosine prodrug (Ade-OA) and ANP-distearoylphosphatidylethanolamine-polyethylene glycol were synthesized. ANP-modified Ade-loaded lipid nanocarriers (ANP Ade/LNCs) were then self-assembled by using solvent evaporation method. In vitro drug release in the presence of plasma was evaluated. In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics were investigated in rats with ischemic myocardium after intravenous injection.
Results: In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics studies in acute myocardial infarction (AMI) rats showed that ANP Ade/LNCs exhibited better efficiency than non-modified Ade/LNCs and free Ade in all respects.
Conclusion: These results indicated that the ANP Ade/LNCs can be used as a promising system for the treatment of cardiovascular diseases.
Keywords: myocardial infarction, atrial natriuretic peptide, lipid nanoparticles, adenosine, prodrug
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]